Navigation Links
Digitas Health Expands Adding Two Key Locations
Date:7/27/2009

erling in 2007. (2)

Digitas Health Boston

Digitas Health Boston is located within the Boston headquarters of parent company Digitas, which offers a deep reservoir of talent and represents an important extension of the health brand's domestic footprint. As the nature of healthcare marketing becomes more sophisticated, Digitas Health is eager to draw on the skill sets of those who have launched some the world's most creative and successful marketing campaigns for clients across leading consumer industries such as automotive, hospitality and finance, and to share that knowledge base across the agency. Serving as the lead marketing and creative executives in Boston are Kirk Williamson, SVP/Marketing and Michael Tiedemann, SVP/Creative, both of whom bring a rich background of accomplishment.

"A simultaneous expansion to sister city Boston allows us the opportunity to reach the talented people within Digitas and beyond who have healthcare and emerging media experience and the significant interest to expand this very successful Digitas Health concept for our clients across the globe," said Kramer.

Leading marketing efforts, Kirk Williamson brings 18 years of consumer and healthcare marketing and general management experience to the role, including several years with Gillette/Procter & Gamble, Bristol-Myers Squibb, and Frito-Lay. He also served as an independent consultant in the consumer health and device markets.

As creative lead, Michael Tiedemann transitioned to the role from parent company Digitas, where he had worked for a decade as the relationship creative lead for many of the company's highest profile clients in the automotive and financial services industries. Additionally, as creative director for the Digital Solutions Group at Prodigious, a Digitas company that is the world's only standalone, global digital productions company, Tiedemann standardized the user expe
'/>"/>

SOURCE Digitas Health
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...arbleEnergyCorp.announcedtodaythatthecompanyandthe...awarded$2millionbyWashingtonState,sCommunityEconom...rshiptoconstructthestate,sfirstspecialtybiochemica...entwillsignificantlyspeedthedevelopmentofourbioref...lueMarbleEnergyCEOKellyOgilvie."Wearegratefultothe...
(Date:11/24/2009)...tCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),thegloba...thatithassubmittedaMAAtotheEuropeanMedicinesAgency...ttherapyindevelopment,forthetreatmentofType1Gauche...aglucerasealfathathasbeensubmitted,withprevious,su...naglobalsupplyshortageofthecurrentlyapprovedandmar...
(Date:11/24/2009)...s Customers with Partners Validated to Process and...ts , Ottawa, ON (PRWEB) N...der of products for biological sample collection, ... new global partner program. The program offers si...ommunity and is designed to help partners scale an...
(Date:11/23/2009)... origami very high-tech origami. , Researchers a...nique for fabricating three-dimensional, single-cr...upling photolithography and a self-folding process...nly a few microns thick, offer mechanical bendabil...e same material. , "This is a completely differen...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
... (Nasdaq: DCTH ) today announced the appointment...rectors. Dr. Stoll is Executive Chairman of Corte...ology company specializing in the treatment of cen... http://www.newscom.com/cgi-bin/prnh/20081118/NY46...toll worked as a consultant to several east coast ...
...orporation,(Nasdaq: PRXL ), a leading global bio...hat it has established an alliance with Safe Imple...onal, the world,s largest network of,clinical site...oke. Through,this alliance, PAREXEL,s clients bene...r sites located in 40 countries, which are dedicat...
...armaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) an...ons following the failure of the Bicifadine Phase ...employment of 9 employees,representing 75% of its ...sible for seeking potential assets or a company to...on and/or disposition of XTL,s assets. , Cau...
Other Biology Technology:Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 2PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 3PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 4
(Date:11/23/2009)...RE, Calif. - By producing some of the highest reso...faces, scientists have a deeper understanding how ...research may lead to a new treatment for kidney st...ppears in the Nov. 23 online edition of the journa... , explores how peptides interact with mineral sur...
(Date:11/23/2009)...MINGHAM, Ala. A new study by University of Alabam...mass index (BMI) and co-existing medical condition...ival observed among African-Americans compared to ...s published online Nov. 23 in Cancer , a journal ...dicates that although BMI and co-morbidity are ind...
(Date:11/23/2009)...GN, Ill. Two new studies reveal in unprecedented ...ules to assemble new proteins and guide them towar...es used molecular dynamics flexible fitting (MDFF)...wo prominent molecular partners. , The first st...iences , concerns the intimate signaling between t...
Breaking Biology News(10 mins):Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 1Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 1Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 1Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 2Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 3Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 4Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 5Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 6Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 8Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 9Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 10Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 11Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 13Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 14Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 15Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 16Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 17Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 18
...veal where a brain cell came from remain distinct ...rnational coalition of scientists will report in t...ding adds a new layer of complexity to the quest t..., according to senior author David H. Gutmann, M.D...f Neurology at Washington University School of Med...
...he risk of HIV transmission may be highest in the ...ublished in the April 1 issue of The Journal of In...ection accounted for nearly half of all transmissi...e province of Quebec, Canada. , Bluma Brenner, PhD...e in Montreal, and colleagues from several hospita...
...e noise, says a team of Rutgers-Camden professors ...he benefits of noise. Their findings could lead to...awei Hong, an assistant professor of computer scie...lliam Saidel, an associate professor of biology, a...fits of noise through mathematics. Although the Ru...
Other Biology News:Genetic fingerprints identify brain tumors' origins 2Risk of HIV transmission highest early in infection 2Noise echoes in cell communications 2
... a base medium for preparation of minimal and synt...ulfate but does not contain amino acids. Both bulk... Each pouch contains reagents to prepare 500 ml of...r S. cerevisiae media. Store at 15C to 30C. Guaran...
...ons are cytopathic effect inhibition assays, also ...tion assay measures the antibody's ability to neut...pes include; tissue culture supernatents; serum an...t is defined as the quantity of interferon require...
Rabbit Anti-Shigella Polyclonal Antibody, Unconjugated from GeneTex
...dy is a mouse monoclonal antibody (IgG1) with high...(GST) domain from S. japonicum . This purified ant...ntaining the GSTTag sequence expressed in E. coli ...nslation systems by Western blotting, immunofluore...
Biology Products: